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Abstract
Serum Amyloid A (SAA) is an acute phase protein complex consisting of several abundant
isoforms. The N- terminus of SAA is critical to its function in amyloid formation. SAA is fre-
quently truncated, either missing an arginine or an arginine-serine dipeptide, resulting in iso-
forms that may influence the capacity to form amyloid. However, the relative abundance of
truncated SAA in diabetes and chronic kidney disease is not known.
Methods
Using mass spectrometric immunoassay, the abundance of SAA truncations relative to the
native variants was examined in plasma of 91 participants with type 2 diabetes and chronic
kidney disease and 69 participants without diabetes.
Results
The ratio of SAA 1.1 (missing N-terminal arginine) to native SAA 1.1 was lower in diabetics
compared to non-diabetics (p = 0.004), and in males compared to females (p<0.001). This
ratio was negatively correlated with glycated hemoglobin (r = −0.32, p<0.001) and triglyceride
concentrations (r = −0.37, p<0.001), and positively correlated with HDL cholesterol concen-
trations (r = 0.32, p<0.001).
Conclusion
The relative abundance of the N-terminal arginine truncation of SAA1.1 is significantly de-
creased in diabetes and negatively correlates with measures of glycemic and lipid control.
Introduction
Serum Amyloid A (SAA) proteins are members of the acute phase response protein group that
play a significant role in inflammatory processes [1]. Structurally, proteins in the SAA complex
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are encoded by four genes; SAA 1 and SAA 2 genes code acute phase SAA protein isoforms,
SAA 3 is not expressed in humans, while SAA 4 is constitutively expressed under homeostatic
conditions but does not vary significantly in the acute phase [2]. SAA 1 and SAA 2 genes give
rise to five SAA 1 (SAA 1.1, SAA 1.2, SAA 1.3, SAA 1.4 and SAA 1.5) and two SAA 2 (SAA 2.1
and SAA 2.2) protein isoforms, respectively. All these protein products share a high degree of
homology and differ only by a few amino acids in their sequences. Only SAA 1.1, SAA 1.2,
SAA 1.3, SAA 2.1 and SAA 2.2 have been identified in humans [3] .
Following an inflammatory stimulus, SAA proteins act as apolipoproteins and become a
major component of high density lipoproteins (HDL). This process removes cholesterol and
extracellular lipid deposits at the inflammation site, but can reduce the ant-inflammatory ca-
pacity of HDL [4–6]. SAA is also chronically elevated in the setting of secondary amyloidosis
leading systemic deposition of SAA-derived truncated fibrils (AA proteins) in tissues [7]. Sec-
ondary amyloidosis has been associated with chronic inflammatory conditions such as rheu-
matoid arthritis [8] or multiple sclerosis [9].In addition, SAA is recognized as a potential
biomarker for a variety of chronic diseases including diabetes, cardiovascular disease (CVD),
different types of cancers, sickle-cell disease, traumatic tissue damage and infections [10–13].
The role of SAA in each of these many conditions is generally believed to be a consequence
of increases in total plasma concentration. However, not all studies find associations between
disease and concentrations of total SAA. The discrepant results may be accounted for by the
fact that most SAA studies do not discriminate between different molecular species of SAA,
and do not consider the posttranslational modifications of the protein [14]. In fact, some stud-
ies demonstrate variations in the relative abundance of SAA truncated at the N-terminus
[3,15,16]. This may have important clinical implications as the N-terminus of SAA is critical
for amyloid fibrils formation [17,18]. The clearance of this truncated SAA variant is different
compared to native SAA suggesting that these truncations may affect the capacity to form amy-
loid [16]. Therefore, it would be important to study if the relative abundances of the truncated
forms differ in patients with chronic conditions such as diabetes or chronic kidney disease
(CKD).
Current analytical techniques for SAA based on conventional immunoassay approaches
provide total protein quantification. However, several mass-spectrometry based methods can
distinguish between the different protein variants and posttranslational SAA protein modifica-
tions [12,19,20] . Mass spectrometric immunoassay (MSIA) is a high throughput methodology
that is well suited to identify and quantify molecular variants and posttranslational modifica-
tions of plasma proteins [21,22]. MSIA is based on the isolation of protein moieties from a bio-
logical milieu by immobilized antibodies, which is followed by mass spectrometry assay. In our
previous work using MSIA, we identified several novel N-terminal truncations of SAA 1.1,
SAA1.2 and SAA 2.1 in human plasma [3]. In the present study, we investigate the association
of SAA truncations with type 2 diabetes and chronic kidney disease (CKD).
Materials and Methods
Clinical Samples
The study was approved by the University of Arizona Institutional Review Board, and all pa-
tients provided written informed consent prior to testing. Two groups of adult participants
(>18 years of age) were recruited: participants with type 2 diabetes (n = 91; 47 males and 44
females) and non-diabetic controls (n = 69, 29 males and 40 females). Participants reported to
the Center for Clinical and Translational Sciences after an overnight fast. Blood was collected
for clinical laboratory measurements (lipid profile, HbA1c, CRP, fasting insulin). Additional
samples were collected in EDTA tubes, and plasma from these samples was separated and
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immediately frozen at −80°C for all other assays. Demographic information (age, sex, ethnici-
ty), physical exam measurements (blood pressure, waist circumference, weight, height, body
mass index), medication use, and medical history (hypertension, hyperlipidemia, smoking,
type and duration of diabetes) were also recorded. The glomerular filtration rate (GFR) was es-
timated using the Modification of Diet in Renal Disease Study (MDRD) equation [23]. Assign-
ment of CKD (stages 1–5) was based on GFR levels as described [24]. Exclusion criteria
included the following: type 1 diabetes, participation in an active weight loss program, history
of cancer, HIV, active infection, other ongoing serious illness or current steroid use. Diabetes
classification was based on clinical and medication history, or glycated hemoglobin greater
than 6%. For the SAAMSIA analysis, frozen plasma samples were briefly thawed on ice, centri-
fuged for 5 min at 3000 rpm, and 50 mL aliquoted in low profile 96-well trays. Prior to the anal-
ysis, samples were diluted with 100 mL PBS containing 0.1%Tween.
Reagents
Monoclonal mouse anti-human antibody to serum amyloid A (SAA) was obtained from
ANOGEN (Mississauga, ON, Canada, Catalog No. MO-C40028A, 500 mg). Protein calibration
standard I (Cat. No. 206355) was purchased from Bruker (Billerica, MA). Phosphate buffered
saline (PBS) buffer (Cat. No. 28372), MES buffered saline (28390), 1, 1’carbonyldiimidazole
(97%) (CDI, 530-62-1), acetonitrile (ACN, A955-4), hydrochloric acid (HCl, A144-212), N-
Methylpyrrolidinone (NMP, BP1172-4) and affinity pipettes fitted with porous microcolumns
(991CUS01) were obtained from Thermo Scientific (Waltham, MA, USA). Tween 20 (Cat. No.
P7949), trifluoroacetic acid (TFA, 299537-100G), sinapic acid (85429-5G), sodium chloride
(S7653), HEPES (H3375), ethanolamine (ETA, 398136), albumin from bovine serum (BSA,
A7906), ammonium acetate (A7330), octyl β-D glucopyranoside (NOG, 08001), polyethylene
glycol (P3015-250G), calcium chloride (C1016-100G), and glycine buffer (G8898-500G) were
obtained from Sigma Aldrich (St. Louis, MO, USA). Acetone (Cat. No. 0000017150) was ob-
tained from Avantor Performance Materials (Center Valley, PA, USA). Plasma SAA was mea-
sured by an ELISA Kit (Novex, Cat. No. KHA0012).
Mass spectrometric immunoassay affinity pipette derivatization
The first step in MSIA method development is derivatization of the affinity pipettes with corre-
sponding antibody toward the targeted protein. Using a Multimek 96 pipettor (Beckman Coul-
ter, Brea, CA ) affinity pipettes were derivatized with antibody toward SAA by initial rinse with
200 mMHCl (2 × 20 cycles, each cycle consisting of an aspiration and dispense of a 120 mL vol-
ume), followed by an acetone rinse (1×20 cycles). The surface of the microcolumns was activat-
ed by immersing the pipettes into a tray containing 100 mg/mL 1, 1’carbonyldiimidazole (in
N-Methylpyrrolidinone), and 450 cycles of 100 mL aspirations and dispenses through each of
the affinity pipettes were performed. Two rinses with NMP (10 cycles each, 150 mL volume)
followed. The affinity pipettes were then immersed into a microwell plate containing the anti-
body solution (5 mg Ab per tip) and 750 cycles of aspirations and dispenses of 50 mL volume
were performed to bind the antibody to the activated surfaces. One rinse with 60 mMHCl fol-
lowed (50 cycles each, 100 mL), ending with two final rinses with assay buffer (PBS w/0.1%
Tween, 50 cycles each, 100 mL). Antibody-derivatized pipettes were stored at +4°C until used.
Mass spectrometric immunoassay
Prior to sample protein extraction, the derivatized affinity pipettes were pre-rinsed with assay
buffer (PBS, 0.1%Tween, 50 aspiration/dispense cycles, 100 mL each), followed by two 60 mM
HCL rinses (50 aspiration/dispense cycles, 100 mL each) and another assay buffer rinse. Based
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on prior experiments, pre-rinsing reduces non-specific binding to the tips during protein ex-
traction. Pipettes were then immersed into a microplate containing the samples and 250 aspira-
tions and dispense cycles were performed (100 mL each) allowing for affinity capture of SAA
from the samples. The pipettes were then rinsed with mixture of 1 M ammonium acetate and
acetonitrile (AA: ACN = 3:1 (v/v)) (100 cycles), and twice with water (10 cycles and 20 cycles
respectively, 100 mL aspiration/dispense each). SAA-loaded tips were then exposed to six-mi-
croliter aliquots of MALDI matrix solution (25 g/L sinapic acid in aqueous solution containing
33% (v/v) acetonitrile, and 0.4% (v/v) trifluoroacetic acid). After a 10 second delay (to allow for
the dissociation of the protein from the capturing antibody), the eluates were dispensed directly
onto a 96-well formatted MALDI target. Following drying, linear-mode mass spectra were ac-
quired from each sample spot, each consisting of ten thousand laser shots using an Autoflex III
MALDI-TOF mass spectrometer (Bruker, Billerica, MA). The mass spectra were internally cali-
brated using low molecular mass protein standards, and further processed (baseline subtracted
and smoothed) with the Flex Analysis software (Bruker Daltonics). Antibody specificity was
verified by confirming the absence of SAA-related mass spectral peaks from negative control
tips on which 1) no antibody was present, and 2) on which monoclonal antibodies specific to
other proteins were immobilized. The peak areas for all SAA signals were measured in Zebra
software (Beavis Informatics, Ltd.). Relative percent abundance of every SAA isoform was cal-
culated in correspondence to the total SAA in the corresponding mass spectra.
SAA quantification
Total SAA concentrations were measured using a commercial ELISA from Invitrogen Life
technologies (Novex, Cat. KHA0012) that has been extensively used [25–29] and tested on
serum, plasma and tissue culture samples. The kit is based on antibody affinity to SAA 1.1, and
thus does not capture the other forms of SAA.
Statistical Analysis
Mean (SD) or median (25th and 75th percentiles) were calculated for continuous variables. The
diabetes and non-diabetes groups were compared by independent t-tests (normally distributed
variables) or Wilcoxon rank sum tests (non-normally distributed variables). Categorical variables
were compared using the chi-square test. The relationship between SAA variants and diabetes
status was measured by logistic regression, with diabetes status as the binary dependent variable.
The relation between SAA truncations and clinical variables was modeled using linear regression;
all regression models used log-transformed SAA 1.1R as the dependent variable, and included
age, BMI, and GFR as adjusting covariates. Regression models were performed in the total sample
and by gender; a product interaction term tested whether the associations of clinical variables
with SAA variants differed in males vs. females. Statistical analyses used SAS version 9.3 software
package; a p-value of< 0.007 (0.05 divided by 7) was used to define significance levels in the
SAA variants between the diabetes and non-diabetes groups accounting for the seven SAA vari-
ants (SAA 1.1R, SAA 1.1RS, SAA 2.1R, SAA 2.1 RS, SAA 2.2R, SAA 1.3R and SAA 1.3 RS trunca-
tions) of interest in this study. All other statistical tests used a p-value of 0.05.
Results
Participants’ demographic and biochemical characteristics are summarized in Table 1. Partici-
pants with diabetes were on average older, had greater BMI, and demonstrated several meta-
bolic characteristics of type 2 diabetes, including low HDL cholesterol, increased fasting insulin
and elevated CRP levels when compared to participants without diabetes. In addition, partici-
pants with diabetes had a lower GFR and a greater urine albumin excretion (p<0.01 for both)
SAA Truncations in Diabetes
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compared with the non-diabetic controls. Males (in the combined group) had significantly
lower GFR than females (mean SD: male: 85.6 32.5 L/min/1.73m2; female: 98.4 35.6
L/min/1.73m2, p = 0.03).
Total SAA concentration was evaluated using a commercial ELISA in an unselected subset
of samples (non-diabetes n = 21 vs. diabetes n = 21). There was no significant difference in
total SAA concentration between the non-diabetes and diabetes groups: (median (25th percen-
tile, 75th percentile), non-diabetes: 28.7 (17.3, 44.5), diabetes: 21.2 (9.9, 38.6), p = 0.21).
Characteristics of known SAA variants are summarized in Table 2. The SAA variants that can
be resolved by MSIA are summarized in Table 3. A total of four protein isoforms, SAA 1.1, SAA
1.3, SAA 2.1 and SAA 2.2 (reflecting protein products from SAA1 and SAA2 genes) were de-
tected among the samples, expressed either as single or as multiple variants. MALDI-MSIA-mass
spectra of SAA from five different plasma samples showing all the variant forms and truncations
(missing terminal –R and/or terminal –RS) are shown in Fig. 1. All samples that expressed SAA
1.1, presented with R and RS truncations. The MSIA analysis confirmed that the SAA variant 1.1
(MW = 11682.68) was the most abundant and it was detected in all but one (159/160) individual.
The distribution of the other identified SAA protein entities within the cohort was as follows:
58.8% for SAA 2.1, 13.1% for SAA 2.2 and 11.9% for SAA 1.3. In addition to these native forms,
twoN-terminal truncation isoforms were noted for all the variants: those missing arginine (des-
R; Δm = −156.19 Da) and/or arginine-serine dipeptide (des-RS; Δm = −243.27 Da).
The relative abundance of each of the truncated isoforms was calculated as the ratio of trun-
cated SAA to native SAA and compared between subjects with and without diabetes (SAA
Table 1. Demographic and clinical characteristics.
Characteristic N1/ N2 No diabetes Diabetes p-value
Age, years 69 / 91 49.4 (15.1) 56.5 (12.8) 0.002
Sex 69 / 91
Male 29 (42.0%) 47 (51.6%) 0.23
Female 40 (58.0%) 44 (48.4%)
Race 69 / 91
Caucasians 45 (65.2%) 50 (54.9%) 0.41
Hispanics 21 (30.4%) 35 (38.5%)
Others 3 (4.4%) 6 (6.6%)
Body mass index, kg/m2 69 / 86 27.8 (24.4, 32.8) 33.9 (28.2, 39.6) <0.001
Waist circumference, cm 68 / 80 98.2 (17.2) 115.0 (19.8) <0.001
Glucose, mg/dL 69 / 85 101.0 (93.0, 110.0) 144.0 (118.0, 202.0) <0.001
Hemoglobin A1C, (%) 65 / 77 5.3 (5.1, 5.8) 7.8 (6.5, 9.8) <0.001
LDL cholesterol, mg/dL 68 / 84 117.3 (33.1) 107.7 (38.4) 0.11
HDL cholesterol, mg/dL 68 / 84 52.6 (14.2) 45.2 (12.3) <0.001
Total cholesterol, mg/dL 68 / 84 196.6 (38.7) 186.1 (45.7) 0.14
Triglycerides, mg/dL 68 / 84 131.5 (97.5, 182.5) 163.5 (134.0, 267.0) 0.001
Glomerular FiltrationRate (GFR), L/min/1.73 m2 65 / 76 104.9 (25.1) 81.6 (38.1) <0.001
Fasting Insulin, IU 9.0 (7.0, 14.0) 16.0 (8.0, 26.0) 0.004
Urine Microalbumin,mg/mg creatinine 66 / 78 5.0 (5.0, 9.0) 12.5 (5.0, 61.0) <0.001
Diabetes duration, years 0 / 85 - 9.0 (4.0, 15.0) -
CRP, mg/dL 34 / 64 2.8 (1.0, 6.1) 6.8 (3.0, 12.1) 0.006
Total SAA, ng/mL* 21 / 21 28.7 (17.3, 44.5) 21.2 (9.9, 38.6) 0.21
Mean (SD) or median (25th percentile, 75th percentile) shown for continuous variables (normally distributed or non-normal, respectively).
*Only a subset from the whole sample was evaluated for total SAA concentration by ELISA.
doi:10.1371/journal.pone.0115320.t001
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Table 2. SAA isoforms detected by MSIA.
SAA
gene
SAA
proteins
Amino acid sequence native
form
-R truncated
form
-RS truncated
form
Allelic genes MW MW MW
SAA1 SAA 1.1 RS FFSFLGEAFD GARDMWRAYS DMREANYIGS DKYFHARGNY
DAAKRGPGGV WAAEAISDAR ENIQRFFGHG AEDSLADQAA NEWGRSGKDP
NHFRPAGLPE KY
11682.7 11526.5 11439.4
SAA 1.2 RS FFSFLGEAFD GARDMWRAYS DMREANYIGS DKYFHARGNY
DAAKRGPGGAWAAEVISDAR ENIQRFFGHD AEDSLADQAA NEWGRSGKDP
NHFRPAGLPE KY
11740.7 11584.5 11497.5
SAA 1.3 RS FFSFLGEAFD GARDMWRAYS DMREANYIGS DKYFHARGNY
DAAKRGPGGAWAAEAISDAR ENIQRFFGHG AEDSLADQAA NEWGRSGKDP
NHFRPAGLPE KY
11654.6 11498.4 11411.4
SAA 1.4* RS FFSFLGEAFD GARDMWRAYS DMREANYIGS DKYFHARGNY
DAAKRGPGGAWAAEVISNAR ENIQRFFGHG AEDSLADQAA NEWGRSGKDP
NHFRPAGLPE KY
11681.7 11525.5 11438.4
SAA 1.5* RS FFSFLGEAFD GARDMWRAYS DMREANYIGS DKYFHARGNY
DAAKRGPGGAWAAEVISDAR ENIQRFFGHG AEDSLADQAA NEWGRSGKDP
NHFRPAGLPE KY
11682.7 11526.5 11439.4
SAA2 SAA 2.1 RS FFSFLGEAFD GARDMWRAYS DMREANYIGS DKYFHARGNY
DAAKRGPGGA WAAEVISNAR ENIQRLTGHG AEDSLADQAA NKWGRSGRDP
NHFRPAGLPE KY
11628.7 11472.5 11385.4
SAA 2.2 RS FFSFLGEAFD GARDMWRAYS DMREANYIGS DKYFHARGNY
DAAKRGPGGA WAAEVISNAR ENIQRLTGRG AEDSLADQAA NKWGRSGRDP
NHFRPAGLPE KY
11647.7 11491.5 11404.5
SAA4 SAA 4** ES WRSFFKEALQ GVGDMGRAYW DIMISNHQNS NRYLYARGNY
DAAQRGPGGV WAAKLISRSR VYLQGLIDCY LFGNSSTVLE DSKSNEKAEE
WGRSGKDPDR FRPDGLPKKY
12802.2
SAA exists in multiple forms. The main isoforms expressed are SAA 1.1 and 2.2. MSIA can detect the SAA 1.1, 1.2, 1.3, 2.1 and 2.2. SAA 1.4 and 1.5
cannot be resolved. SAA 3 is a pseudo gene (not expressed). SAA 4 is constitutively expressed. MSIA: Mass Spectrometric Immunoassay.
* These variants can’t be distinguished in the mass spectra due to close proximity (overlapping) of the mass in spite of the changes in the amino acid
sequence.
** SAA 4 is constitutively expressed.
doi:10.1371/journal.pone.0115320.t002
Table 3. Comparison of SAA variant ratios between the diabetes and non-diabetes groups.
SAA Variant Ratio % variants detected N1 / N2 Non-Diabetes Diabetes p-value
SAA 1.1R 99.4% (159/160) 69 / 90 0.93 (0.76, 1.17) 0.84 (0.65, 0.99) 0.004*
SAA 1.1RS 99.4% (159/160) 69 / 90 0.22 (0.18, 0.28) 0.21 (0.15, 0.29) 0.11
SAA 2.1R 57.5% (92/160) 34 / 58 0.88 (0.76, 1.10) 0.90 (0.78, 1.04) 0.73
SAA 2.1RS 29.4% (47/160) 16 / 31 0.25 (0.20, 0.30) 0.25 (0.20, 0.32) 0.96
SAA 2.2R 13.1% (21/160) 6 / 15 0.70 (0.53, 0.89) 0.81 (0.76, 0.93) 0.32
SAA 1.3R 11.9% (19/160) 6 / 13 0.79 (0.74, 1.24) 0.96 (0.80, 1.18) 0.94
SAA 1.3RS 10.6% (17/160) 5 / 12 0.23 (0.23, 0.27) 0.28 (0.22, 0.36) 0.42
SAA isoforms were heavily truncated at the N terminus missing either arginine (R) or arginine serine (RS). The truncation abundance and the differences
in participants with diabetes and without diabetes are summarized. The data are presented as medians (25th percentile, 75th percentile) by diabetes
status. The comparison between the two groups was performed with a logistic regression model after adjusting for age.
*Indicates statistically significant at the threshold of 0.007. After adjusting for age and BMI, the association of diabetes and SAA 1.1R was significant at
the .05 alpha level: OR(95 CI) = 0.24 (0.07 to 0.78), p = 0.02.
doi:10.1371/journal.pone.0115320.t003
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variants R and RS ratios). The log of SAA1.1R ratio was higher in the non-diabetic group com-
pared to the diabetic group, (p = 0.02). The log of SAA1.1R was significantly associated with
age (r = 0.16, p = 0.03), but not with BMI (r = −0.12, p = 0.11). As shown in Table 3, after ad-
justment for age, SAA 1.1R was lower in the diabetes group compared with the non-diabetes
group (p = 0.004); the association remained significant with adjustment for both BMI and age
(p = 0.02). In contrast, the ratio of other SAA truncation variants to native (SAA 1.1RS, 2.1R,
2.1RS, 2.2R, 1.3R and 1.3 RS truncations) did not differ between the diabetes and non-diabetes
groups (all p>0.05, Table 3). In addition, in the whole group (diabetes and non-diabetes com-
bined) the SAA 1.1R ratio to native was lower in males compared with females (median (IQR):
male: n = 76, 0.78 (0.29); female: n = 84, 0.97 (0.43), p<0.001), Fig. 2).
An inverse correlation was observed between glucose levels and log-transformed SAA 1.1R
(r = −0.3, p<0.001). The correlation between log-transformed SAA1.1R and glucose was signif-
icant in males (r = −0.44, p<0.001, Fig. 3B) but not in females (r = −0.15, p = 0.17, Fig. 3C).
Table 4 summarizes the linear associations of log-transformed SAA 1.1R ratio and several met-
abolic measures in males and females, adjusting for age, BMI and GFR. Both fasting glucose
and glycated hemoglobin were strongly inversely correlated with log-transformed SAA 1.1R
ratio. Although none of these associations significantly differed in males and females (all
Figure 1. MALDI-MSIA-mass spectra of SAA from five different plasma samples showing all the variant forms and truncations (missing terminal –
R and/or terminal –RS). All samples express SAA 1.1 with R and RS truncations.
doi:10.1371/journal.pone.0115320.g001
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interaction p-values> 0.05), the SAA 1.1R ratio was most strongly and inversely correlated
with glucose levels in males. There was no correlation between total SAA concentrations mea-
sured by ELISA and the SAA1.1R ratio determined by MSIA.
Since males had a lower GFR than females, the relative abundance of SAA truncations could
be explained by differences in kidney clearance rate. To address this possibility, the relationship
between log-transformed SAA 1.1R and GFR in both males and females was examined.
In males, log-transformed SAA 1.1R was not significantly correlated with GFR (r = 0.21,
p = 0.09); the association was reduced with adjustment for glucose (r = 0.12, p = 0.37). In
females, log-transformed SAA1.1R and GFR were inversely but not significantly correlated
(r = −0.221, p = 0.06); adjustment for glucose did not alter this association (r = −0.21, p = 0.08).
These glucose-adjusted associations did not significantly differ among males and females
(p-value for interaction = 0.09).
The study group was categorized by CKD stage with the non-CKD group defined based
on a GFR > 90 L/min/1.73m2. The distribution of CKD stages in the diabetes and non-
diabetes groups is presented in Table 5. There were 61 patients in the CKD group and 80 pa-
tients in the non-CKD group. The majority of non-diabetic participants did not have evi-
dence of CKD, whereas the diabetic participants recruited in this study had different stages
of CKD with 9 participants in stages 4 and 5. The inverse association of log-transformed
SAA1.1R with glucose did not differ among persons with CKD vs. non-CKD (interaction
p-value = 0.12, adjusted for age and BMI). These findings confirm that glucose levels had an
inverse correlation with SAA 1.1R, with the association apparent in persons with and with-
out CKD.
The peak area of SAA 1.1 was highly correlated to the peak area of SAA 1.1R and SAA
1.1RS (Table 6). The correlation was strongest (r> 0.9, p<0.001, all subjects) among the
SAA 1.1 R and RS variants suggesting that the same process favors the formation of both
truncations.
Figure 2. SAA variant ratios (median, IQR) amongmales (n = 76) and females (n = 84) group. SAA 1.1R
(missingN-terminal R arginine) ratio to SAA 1.1 was significantly lower in males compared to females
(p<0.001).
doi:10.1371/journal.pone.0115320.g002
SAA Truncations in Diabetes
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Discussion
Our findings demonstrate that ratios of SAA 1.1R truncations to their native SAA variants are
decreased in diabetes. The occurrence of N-terminally truncated SAA has been observed in sev-
eral studies confirming that the relative abundance of this variant of SAA is quite high
Figure 3. Correlation between glucose and the log of SAA 1.1R ratio in the entire group (panel a), in
males (panel b), and in females (panel c). In the entire group, the log of SAA 1.1R was inversely related to
glucose levels (panel a, r = −0.3, p<0.001). This correlation was driven by the males in the study. The log of
SAA 1.1R was inversely correlated to glucose in males (panel b, r= −0.44, p<0.001), but not in females
(panel c, r = −0.15, p = 0.17).
doi:10.1371/journal.pone.0115320.g003
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[3,12,15,16,30,31]. The population frequency of these truncations and their physiologic rele-
vance are not known. Since the N terminus of SAA determines its amyloid fibril formation ac-
tivity [17,18], assessing changes in SAA truncations might provide insight into diseases such as
reactive amyloidosis where susceptibility to amyloid formation is dependent on the SAA func-
tionality and clearance. We previously reported a lower relative abundance of SAA truncations
in plasma of one subject with acute inflammation (rheumatoid arthritis) compared with sub-
jects without evidence of inflammation [3]. Given that the N-terminal arginine and serine of
SAA are highly conserved, these truncations are likely the result of posttranslational modifica-
tions [12,32]. Dipeptidyl aminopeptidase cleavage has been reported for several lipoproteins
[33], and SAA is an apolipoprotein that forms HDL. In our study, glucose levels had the stron-
gest correlation (inverse relationship) with the ratio of truncations in males, and this persisted
after adjusting for changes in kidney function, age or BMI. This inverse relationship with hy-
perglycemia suggests that glucose might impair the peptidase activity. In one previous study,
the clearance of truncated SAA at the N-terminus differed from native SAA suggesting that
these truncations may impact SAA turnover [16].
Our findings also suggest that sex may independently modify the activity of this peptidase,
leading to a lower truncated SAA to native SAA ratio. Of note, male sex was previously
Table 4. Relationship of SAA 1.1R variant ratios with clinical and laboratory characteristics.
Combined sample Male Female
N/N1/N2 Regression
Coefficient
Beta (SE)
p-value Regression
Coefficient
Beta (SE)
p-value Regression
Coefficient
Beta (SE)
p-value
Waist circumference, cm 129/59/70 −0.008(0.003) 0.02 −0.004(0.006) 0.47 −0.002(0.004) 0.59
Glucose,mg/dL 134/62/72 −0.001(0.0004) 0.004 −0.002(0.0004) <0.001 −0.0006(0.0007) 0.41
Glycated Hemoglobin % 128/61/67 −0.040(0.011) <0.001 −0.035(0.010) 0.001 −0.028(0.019) 0.15
Triglycerides,mg/dL 135/62/73 −0.0006(0.0002) 0.01 −0.0003(0.0002) 0.23 −0.0004(0.0004) 0.33
HDL,cholesterolmg/dL 135/62/73 0.007(0.002) 0.003 0.003(0.004) 0.43 0.002(0.003) 0.59
CRP,mg/dL 82/42/40 −0.001(0.006) 0.85 0.0005(0.006) 0.94 −0.005(0.008) 0.52
Linear regression with log-transformed SAA 1.1R as the dependent variable with clinical and laboratory characteristics as the independent variables
adjusted for age, BMI and glomerular filtration rate (GFR).
All samples in table include both diabetics and non-diabetics.
N = number of subjects in combined sample (male and female subjects)
N1 = number of male subjects
N2 = number of female subjects
doi:10.1371/journal.pone.0115320.t004
Table 5. Numbers of participants in non-diabetes and diabetes groups based on their CKD stages.
CKD stage Non-Diabetes N = 65 Diabetes N = 76
Stage1 (GFR 90 mL/min/1.73m2) 46 34
Stage2 (60GFR<90 mL/min/1.73m2) 18 21
Stage3 (30GFR<60 mL/min/1.73m2) 1 12
Stage4 (15GFR<30 mL/min/1.73m2) 0 6
Stage5 (GFR<15 mL/min/1.73m2) 0 3
GFR values for 19 patients were unavailable.
Fisher’s exact test was used to test for differences in CKD stages between diabetics and non-diabetics, p
< 0.001.
doi:10.1371/journal.pone.0115320.t005
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identified as a risk factor for both amyloidosis and diabetes complications. In a study of Famil-
ial Mediterranean Fever, the male to female ratio was significantly higher (2:1) in patients with
reactive amyloidosis, [34]. In the Pittsburgh Epidemiology of Diabetes Complications Study,
males had worse diabetic complications after long term follow up [35]. The role of these trun-
cations in chronic diabetic complications merits further study.
We measured total SAA concentrations by a validated commercial ELISA [25–29]. Total
SAA concentrations did not differ between the diabetic and non-diabetic groups and SAA con-
centrations did not correlate with the ratio of SAA1.1R ratio. Although a previous study [36]
demonstrated that SAA concentrations were increased in type 2 diabetes with chronic kidney
disease, we did not find increased total SAA concentrations in persons with diabetes.
The relative abundance of the SAA RS truncation is lower than that of SAA R, and there has
been speculation that it might be a biomarker of certain diseases, such as renal cancer [12].
However, the strong correlation of R and RS truncations with the unmodified SAA 1.1 variant
suggest that the same process affects the formation of both of these truncations in patients with
and without diabetes (Table 6). This may argue against RS truncation as a selective marker of
diabetes complications.
It is worth noting that MSIA cannot distinguish SAA form 1.5 from 1.1 because their molec-
ular weight differs by only 1 Da, which makes these forms difficult to differentiate from each
other on most mass spectrometers. The expression frequencies of SAA 1.4 and 1.5 are not
known, but based on previous genetic studies, they are likely uncommon variants [37]. Given
the lower relative abundance of SAA 2.1, 2.2 and 1.3 truncations, this study could be under-
powered to detect differences in these variants between the diabetes and non-diabetes groups.
In conclusion, our findings indicate that truncated SAA is less common in diabetes. SAA
truncations may modify SAA function and clearance. Measuring SAA truncations may help us
better understand the susceptibility to reactive amyloidosis in chronic conditions.
Author Contributions
Conceived and designed the experiments: HY CB PR RN. Performed the experiments: HY OT
DN CB. Analyzed the data: HHWMNK. Contributed reagents/materials/analysis tools: RN
CB OT DN. Wrote the paper: HY PR JK CBWMOT.
References
1. Malle E, De Beer FC (1996) Human serum amyloid A (SAA) protein: a prominent acute-phase reactant
for clinical practice. European Journal of Clinical Investigation 26: 427–435. doi: 10.1046/j.1365-2362.
1996.159291.x PMID: 8817153
2. Malle E, Steinmetz A, Raynes JG (1993) Serum amyloid A (SAA): an acute phase protein and apolipo-
protein. Atherosclerosis 102: 131–146. doi: 10.1016/0021-9150(93)90155-N PMID: 7504491
3. Kiernan UA, Tubbs KA, Nedelkov D, Niederkofler EE, Nelson RW (2003) Detection of novel truncated
forms of human serum amyloid A protein in human plasma. FEBS Lett 537: 166–170. doi: 10.1016/
S0014-5793(03)00097-8 PMID: 12606051
Table 6. Correlations between SAA 1.1 variants in diabetes group.
Variants All subjects N = 159 No Diabetes N1 = 69 Diabetes N2 = 90
SAA 1.1 with SAA 1.1R 0.87 0.84 0.90
SAA 1.1 with SAA 1.1RS 0.81 0.78 0.83
SAA 1.1R with SAA 1.1RS 0.91 0.89 0.93
The peak area of log-transformed SAA 1.1 (unmodified) was highly correlated to the peak area of log-transformed SAA 1.1R and SAA 1.1RS (all p-values
<0.001).
doi:10.1371/journal.pone.0115320.t006
SAA Truncations in Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0115320 January 21, 2015 11 / 13
4. Cabana V, Siegel J, Sabesin S (1989) Effects of the acute phase response on the concentration and
density distribution of plasma lipids and apolipoproteins. Journal of lipid research 30: 39–49. PMID:
2493057
5. Liang J, Sipe J (1995) Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modu-
lates cholesterol flux. Journal of lipid research 36: 37–46. PMID: 7706946
6. Tölle M, Huang T, Schuchardt M, Jankowski V, Prüfer N, et al. (2012) High-density lipoprotein loses its
anti-inflammatory capacity by accumulation of pro-inflammatory-serum amyloid A. Cardiovascular re-
search 94: 154–162. doi: 10.1093/cvr/cvs089 PMID: 22328092
7. Elliott B, Liang, Sipe, Cathcart (1998) Catabolism of Lipid-Free Recombinant Apolipoprotein Serum
Amyloid A by Mouse Macrophages In Vitro Results in Removal of the Amyloid Fibril-Forming Amino
Terminus. Scandinavian Journal of Immunology 48: 241–247. doi: 10.1046/j.1365-3083.1998.00384.x
PMID: 9743207
8. Cunnane G (2001) Amyloid precursors and amyloidosis in inflammatory arthritis. Current opinion in
rheumatology 13: 67–73. doi: 10.1097/00002281-200101000-00011 PMID: 11148718
9. Ristori G, Laurenti F, Stacchini P, Gasperini C, Buttinelli C, et al. (1998) Serum amyloid A protein is ele-
vated in relapsing-remitting multiple sclerosis. Journal of neuroimmunology 88: 9–12. doi: 10.1016/
S0165-5728(98)00037-X PMID: 9688318
10. Malle E, Sodin-Semrl S, Kovacevic A (2009) Serum amyloid A: an acute-phase protein involved in tu-
mour pathogenesis. Cell Mol Life Sci 66: 9–26. doi: 10.1007/s00018-008-8321-x PMID: 18726069
11. Zhao Y, He X, Shi X, Huang C, Liu J, et al. (2010) Association between serum amyloid A and obesity: a
meta-analysis and systematic review. InflammRes 59: 323–334. doi: 10.1007/s00011-010-0163-y
PMID: 20140694
12. Tolson J, Bogumil R, Brunst E, Beck H, Elsner R, et al. (2004) Serum protein profiling by SELDI mass
spectrometry: detection of multiple variants of serum amyloid alpha in renal cancer patients. Laboratory
Investigation 84: 845–856. doi: 10.1038/labinvest.3700097 PMID: 15107802
13. Tumblin A, Tailor A, Hoehn GT, Mack AK, Mendelsohn L, et al. (2010) Apolipoprotein AI and serum am-
yloid A plasma levels are biomarkers of acute painful episodes in patients with sickle cell disease. hae-
matologica 95: 1467–1472. doi: 10.3324/haematol.2009.018044 PMID: 20378559
14. Avgerinos ED, Kadoglou NP, Moulakakis KG, Giannakopoulos TG, Liapis CD (2011) Current role of
biomarkers in carotid disease: a systematic review. Int J Stroke 6: 337–345. doi: 10.1111/j.1747-4949.
2011.00623.x PMID: 21745345
15. Beach CM, De Beer MC, Sipe JD, Loose LD, De Beer FC (1992) Human serum amyloid A protein.
Complete amino acid sequence of a new variant. Biochem J 282 (Pt 2): 615–620. PMID: 1546977
16. Raynes JG, McAdam KP (1991) Serum amyloid A isoforms in inflammation. Scand J Immunol 33:
657–666.
17. Westermark GT, Engström U, Westermark P (1992) The N-terminal segment of protein AA determines
its fibrillogenic property. Biochemical and biophysical research communications 182: 27–33. doi: 10.
1016/S0006-291X(05)80107-X PMID: 1731787
18. Egashira M, Takase H, Yamamoto I, Tanaka M, Saito H (2011) Identification of regions responsible for
heparin-induced amyloidogenesis of human serum amyloid A using its fragment peptides. Archives of
biochemistry and biophysics 511: 101–106. doi: 10.1016/j.abb.2011.04.019 PMID: 21569756
19. Farwig ZN, McNeal CJ, Little D, Baisden CE, Macfarlane RD (2005) Novel truncated isoforms of consti-
tutive serum amyloid A detected by MALDI mass spectrometry. Biochemical and biophysical research
communications 332: 352–356. doi: 10.1016/j.bbrc.2005.04.129 PMID: 15910745
20. Ducret A, Bruun CF, Bures EJ, Marhaug G, Husby G, et al. (1996) Characterization of human serum
amyloid A protein isoforms separated by two-dimensional electrophoresis by liquid chromatography/
electrospray ionization tandemmass spectrometry. ELECTROPHORESIS 17: 866–876. doi: 10.1002/
elps.1150170508 PMID: 8783012
21. Nelson RW, Borges CR (2011) Mass spectrometric immunoassay revisited. J Am Soc Mass Spectrom
22: 960–968. doi: 10.1007/s13361-011-0094-z PMID: 21953037
22. Nelson RW, Krone JR, Bieber AL, Williams P (1995) Mass spectrometric immunoassay. Anal Chem
67: 1153–1158. doi: 10.1021/ac00103a003 PMID: 15134097
23. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, et al. (1999) A more accurate method to estimate
glomerular filtration rate from serum creatinine: a new prediction equation. Annals of internal medicine
130: 461–470. doi: 10.7326/0003-4819-130-6-199903160-00002 PMID: 10075613
24. Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, et al. (2010) The definition, classification, and
prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney international
80: 17–28.
SAA Truncations in Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0115320 January 21, 2015 12 / 13
25. Tajima M,Wakita D, Noguchi D, Chamoto K, Yue Z, et al. (2008) IL-6-dependent spontaneous prolifera-
tion is required for the induction of colitogenic IL-17-producing CD8+ T cells. The Journal of experimen-
tal medicine 205: 1019–1027. doi: 10.1084/jem.20071133 PMID: 18426983
26. Sung H-J, Jeon S, Ahn J-M, Seul K-J, Kim JY, et al. (2012) Large-scale isotype-specific quantification
of Serum amyloid A 1/2 by multiple reaction monitoring in crude sera. Journal of proteomics 75: 2170–
2180. doi: 10.1016/j.jprot.2012.01.018 PMID: 22300576
27. Igawa T, Ishii S, Tachibana T, Maeda A, Higuchi Y, et al. (2010) Antibody recycling by engineered pH-
dependent antigen binding improves the duration of antigen neutralization. Nature biotechnology 28:
1203–1207. doi: 10.1038/nbt.1691 PMID: 20953198
28. Malik P, Berisha SZ, Santore J, Agatisa-Boyle C, Brubaker G, et al. (2011) Zymosan-mediated inflam-
mation impairs in vivo reverse cholesterol transport. Journal of lipid research 52: 951–957. doi: 10.
1194/jlr.M011122 PMID: 21335620
29. Vijay-Kumar M, Sanders CJ, Taylor RT, Kumar A, Aitken JD, et al. (2007) Deletion of TLR5 results in
spontaneous colitis in mice. The Journal of clinical investigation 117: 3909–3921. doi: 10.1172/
JCI33084 PMID: 18008007
30. Strachan AF, Brandt WF, Woo P, van der Westhuyzen DR, Coetzee GA, et al. (1989) Human serum
amyloid A protein. The assignment of the six major isoforms to three published gene sequences and
evidence for two genetic loci. Journal of Biological Chemistry 264: 18368–18373. PMID: 2808379
31. Dwulet FE, Wallace DK, Benson MD (1988) Amino acid structures of multiple forms of amyloid-related
serum protein SAA from a single individual. Biochemistry 27: 1677–1682. doi: 10.1021/bi00405a044
PMID: 3130100
32. Skogen B, Natvig JB (1981) Degradation of amyloid proteins by different serine proteases. Scand J
Immunol 14: 389–396. doi: 10.1111/j.1365-3083.1981.tb00579.x PMID: 6461061
33. Gordon JI, Sims HF, Strauss AW, Scanu AM, Edelstein C, et al. (1986) Proteolytic Processing and
Compartmentalization of the Primary Translation Products of Mammalian Apolipoprotein Mrna. Critical
Reviews in Biochemistry and Molecular Biology 20: 37–71. doi: 10.3109/10409238609115900 PMID:
3514123
34. Gershoni-Baruch R, Brik R, Lidar M, Shinawi M, Livneh A (2003) Male sex coupled with articular mani-
festations cause a 4-fold increase in susceptibility to amyloidosis in patients with familial Mediterranean
fever homozygous for the M694V-MEFVmutation. The Journal of rheumatology 30: 308–312. PMID:
12563686
35. Orchard TJ, Dorman JS, Maser RE, Becker DJ, Drash AL, et al. (1990) Prevalence of complications in
IDDM by sex and duration: Pittsburgh Epidemiology of Diabetes Complications Study II. Diabetes 39:
1116–1124. doi: 10.2337/diabetes.39.9.1116 PMID: 2384191
36. Tsun J, Shiu S, Wong Y, Yung S, Chan T, et al. (2013) Impact of serum amyloid A on cellular cholester-
ol efflux to serum in type 2 diabetes mellitus. Atherosclerosis 231: 405–410. doi: 10.1016/j.
atherosclerosis.2013.10.008 PMID: 24267259
37. Steinkasserer A, Weiss EH, SchwaebleW, Linke RP (1990) Heterogeneity of human serum amyloid A
protein. Five different variants from one individual demonstrated by cDNA sequence analysis. Biochem
J 268: 187–193. PMID: 1971508
SAA Truncations in Diabetes
PLOS ONE | DOI:10.1371/journal.pone.0115320 January 21, 2015 13 / 13
